CV Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

12. SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2016

	Consumer Products Segment			Specialty Pharmaceutical Segment			Consolidated Totals
Three Months Ended
September 30, 2016:
Product sales, net	$	2,939,997		$	–		$	2,939,997
Gross profit		1,888,949			–			1,888,949
Selling, general and administrative		2,952,533			119,908			3,072,441
Research and development		292,738			103,500			396,238
Operating (loss) income	$	(1,356,322	)	$	(223,408	)	$	(1,579,730	)

September 30, 2015:
Product sales, net	$	4,151,180		$	–		$	4,151,180
Gross profit		2,458,797			–			2,458,797
Litigation settlement income		756,714			–			756,714
Selling, general and administrative		3,888,898			–			3,888,898
Research and development		228,822			–			228,822
Operating (loss) income	$	(902,209	)	$	–		$	(902,209	)

Nine Months Ended
September 30, 2016:
Product sales, net	$	7,850,430		$	–		$	7,850,430
Gross profit		5,178,911			–			5,178,911
Selling, general and administrative		8,904,694			242,717			9,147,411
Research and development		658,817			220,781			879,598
Operating (loss) income	$	(4,384,600	)	$	(463,498	)	$	(4,848,098	)

September 30, 2015:
Product sales, net	$	9,279,117		$	–		$	9,279,117
Gross profit		5,365,497			–			5,365,497
Litigation settlement income		756,714			–			756,714
Selling, general and administrative		10,716,814			–			10,716,814
Research and development		972,844			–			972,844
Operating (loss) income	$	(5,567,447	)	$	–		$	(5,567,447	)